Analysis of patient characteristics and safety of insulin glargine <scp>U300</scp> use in 21 359 patients with type‐2 diabetes and chronic kidney disease: <scp>DPV</scp> registry study
Despite variations in patient profiles, Gla-300 is widely used across all CKD stages, particularly in advanced stages with a low rate of severe hypoglycemia, suggesting its safe administration in CKD patients.
Authors
- Frank J. Wosch
- Reinhard W. Holl (ORCID: https://orcid.org/0000-0003-1395-4842)
- Nicole Forestier
- Markus Rottmann (ORCID: https://orcid.org/0000-0002-5759-2639)
- Jochen Seufert (ORCID: https://orcid.org/0000-0001-5654-7310)
- Gregor Hess
- Stefanie Lanzinger (ORCID: https://orcid.org/0000-0002-3789-6459)
- Peter Bramlage (ORCID: https://orcid.org/0000-0003-4970-2110)
- Anjaly Vijayan (ORCID: https://orcid.org/0009-0009-0915-427X)
Institutions
- University of Applied Sciences Worms (DE)
- University of Freiburg (DE)
- Universität Ulm (DE)
- Klinikum Hanau (DE)
- IPPMed (Germany) (DE)
- Zimmer Biomet (Germany) (DE)
- Schön Klinik Bad Aibling (DE)
- Deutsches Diabetes-Zentrum e.V. (DE)
- German Center for Diabetes Research (DE)
- Heinrich Heine University Düsseldorf (DE)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2025-02-19
- DOI
- https://doi.org/10.1111/dom.16245
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00